Holen Sie sich die Stockscreener-App
0.8899
0.01%
-0.000100
Handel nachbörslich:
.82
-0.0699
-7.85%
Schlusskurs vom Vortag:
$0.89
Offen:
$0.861919
24-Stunden-Volumen:
5,235
Relative Volume:
0.04
Marktkapitalisierung:
$32.21M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-8.53M
KGV:
-7.6321
EPS:
-0.1166
Netto-Cashflow:
$-12.75M
1W Leistung:
+16.86%
1M Leistung:
+2.29%
6M Leistung:
-12.33%
1J Leistung:
-28.81%
1-Tages-Spanne:
$0.8101
$0.8899
1-Wochen-Bereich:
$0.74
$0.90
52-Wochen-Spanne:
$0.63
$3.23
Estrella Immunopharma Inc Stock (ESLA) Company Profile
Firmenname
Estrella Immunopharma Inc
Sektor
Branche
Telefon
(510) 318-9098
Adresse
5858 HORTON STREET, SUITE 370, EMERYVILLE
Vergleichen Sie ESLA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| ESLA | 0.8899 | 32.21M | 0 | -8.53M | -12.75M | -0.1166 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
Estrella Immunopharma Inc Aktie (ESLA) Neueste Nachrichten
Estrella Immunopharma Inc (ESLA) Quarterly 10-Q Report - Quartzy
Spotlight On US Penny Stocks: Estrella Immunopharma And Two Others To Consider - Simply Wall St
Estrella Immunopharma Appoints Dr. Cheng Liu as CEO - TipRanks
Decoding Houlihan Lokey Inc (HLI): A Strategic SWOT Insight - Yahoo Finance Australia
Tesla stock hits 52-week low at $0.75 amid market challenges - Investing.com
ARMOUR Residential REIT, Inc. Announces November 2024 Dividend Rate per Common Share - Yahoo Finance Australia
Westrock Coffee Company (WEST) Moves 10.8% Higher: Will This Strength Last? - Yahoo Finance Australia
First Patient Dosed Achieves Complete Response in Estrella Immunopharma’s Trial for CD19-Targeted T-cell Therapy EB103 in B-Cell Lymphomas - CGTLive™
HP Inc. gets hit with downgrade from Citigroup - Yahoo Finance Australia
Estrella Immunopharma Inc (ESLA) Stock: A Year of Stock Market Dynamics - The InvestChronicle
Stocks to Watch: Wynn Resorts, Estrella Immunopharma, Amazon.com - MarketWatch
Stocks to Watch : Wynn Resorts, Estrella Immunopharma, Amazon.com - Marketscreener.com
BeyondSpring (BYSI) Stock Surges 6.83% Amid High Volume Trading - GuruFocus.com
Estrella Immunopharma Shares Rise on Lymphoma Patient's Treatment Response - MarketWatch
Estrella Immunopharma Achieves Complete Response in First Patient Treated with CD19- Redirected ARTEMIS - Business Wire
Allogene Therapeutics (ALLO) Stock Jumps by 5.15% - GuruFocus.com
Best Income Stocks to Buy for September 25th - Yahoo Finance Australia
vTv Therapeutics (NASDAQ:VTVT) Stock Quotes, Forecast and News Summary - Benzinga
EXTR INVESTOR UPDATE: Suffer Losses on Your Extreme Networks, Inc. Investment? Contact BFA Law by October 15 about Pending Class Action Lawsuit (Nasdaq:EXTR) - ForexTV.com
Arizona State Retirement System Has $78,000 Stock Holdings in Evolv Technologies Holdings, Inc. (NASDAQ:EVLV) - Defense World
Shareholders that lost money on Extreme Networks, Inc. (EXTR) Urged to Join Class Action – Contact The Gross Law Firm to Learn More - ForexTV.com
Elutia Inc. (NASDAQ:ELUT) Sees Large Decrease in Short Interest - Defense World
Kessler Topaz Meltzer & Check, LLP Reminds Investors of - GlobeNewswire
Extra Storage rises on Jefferies upgrade - XM
Debt-Free Multibagger Stock Hit 18 Consecutive Upper Circuits & 52-Week Highs: Will the Rally Come to a Halt? - Dalal Street Investment Journal
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Extreme Networks, Inc.EXTR - PR Newswire
Extreme Networks (EXTR) Tumbled 18% After Guiding For - GlobeNewswire
Clene (NASDAQ:CLNN) Stock Quotes, Forecast and News Summary - Benzinga
The Psychology of Extreme Networks Inc. Inc. (EXTR) Price Performance: Understanding Market Sentiment - The InvestChronicle
Despite selling recently, Dell Technologies Inc. (NYSE:DELL) insiders own 50% stake and recent decline might have cost them - Yahoo Finance Australia
Estrella Immunopharma Welcomes New Chairperson, Expands Board - TipRanks
Here is What to Know Beyond Why PayPal Holdings, Inc. (PYPL) is a Trending Stock - Yahoo Finance Australia
Uptake of Nononcology Gene Therapy Remains Slow in Hematology - CGTLive™
Estrella Immunopharma appoints new chairperson to board - Investing.com India
Estrella Immunopharma Announces Appointment of Hong Zhang as Chairperson and Board Member - 01Net
ESLAWEstrella Immunopharma, Inc. Warrant Latest Stock News & Market Updates - StockTitan
Estrella Immunopharma, Inc. (NASDAQ:ESLA) Sees Large Growth in Short Interest - MarketBeat
Wall Street today: US stocks trade higher after promising inflation data raises Fed rate cut bets; 3M Co. gains 18.99% - MSN
Estrella Immunopharma’s Trial for CD19-Targeted T-cell Therapy EB103 in B-Cell Lymphomas Doses First Patient - CGTLive™
Estrella Immunopharma, Inc. (NASDAQ:ESLA) Short Interest Up 8.5% in July - MarketBeat
ESLA’s Stock Tango: The Dance of Gains and Losses in 2023 - The InvestChronicle
Wall Street today: US stocks trade higher after promising inflation data raises Fed rate cut bets; 3M Co. gains 18.99% | Stock Market News - Mint
Keppel REIT (OTCMKTS:KREVF) Sees Large Growth in Short Interest - American Banking and Market News
Apple Inc. (NASDAQ:AAPL) Shares Acquired by Saxon Interests Inc. - American Banking and Market News
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Short Interest Up 24.9% in June - American Banking and Market News
Estrella Immunopharma, Inc. (NASDAQ:ESLA) Short Interest Up 60.0% in June - MarketBeat
Estrella Immunopharma, Inc. (NASDAQ:ESLA) Short Interest Update - Defense World
Around the Helix: Cell and Gene Therapy Company Updates – July 10, 2024 - CGTLive™
Estrella Immunopharma streamlines operations with subsidiary merger By Investing.com - Investing.com India
ZUU Co. Ltd. executives purchase Pono Capital two shares worth $390 By Investing.com - Investing.com
Maersk exits DB Schenker bid; Citi reaffirms sell rating on stock By Investing.com - Investing.com
Finanzdaten der Estrella Immunopharma Inc-Aktie (ESLA)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.66%
1.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):